These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 26415901)

  • 1. Depression--An emerging indication for botulinum toxin treatment.
    Kruger TH; Wollmer MA
    Toxicon; 2015 Dec; 107(Pt A):154-7. PubMed ID: 26415901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shrink that frown! Botulinum toxin therapy is lifting the face of psychiatry.
    Wollmer MA; Neumann I; Magid M; Kruger TH
    G Ital Dermatol Venereol; 2018 Aug; 153(4):540-548. PubMed ID: 29667799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Use of Botulinum Toxin for Treatment of Depression.
    Wollmer MA; Magid M; Kruger THC; Finzi E
    Handb Exp Pharmacol; 2021; 263():265-278. PubMed ID: 31691857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
    Dessy LA; Fallico N; Mazzocchi M; Scuderi N
    Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facing depression with botulinum toxin: a randomized controlled trial.
    Wollmer MA; de Boer C; Kalak N; Beck J; Götz T; Schmidt T; Hodzic M; Bayer U; Kollmann T; Kollewe K; Sönmez D; Duntsch K; Haug MD; Schedlowski M; Hatzinger M; Dressler D; Brand S; Holsboer-Trachsler E; Kruger TH
    J Psychiatr Res; 2012 May; 46(5):574-81. PubMed ID: 22364892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Botulinum toxin for the treatment of major depressive disorder].
    Hawlik AE; Freudenmann RW; Pinkhardt EH; Schönfeldt-Lecuona CJ; Gahr M
    Fortschr Neurol Psychiatr; 2014 Feb; 82(2):93-9. PubMed ID: 24519192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of depression with botulinum toxin A: a case series.
    Finzi E; Wasserman E
    Dermatol Surg; 2006 May; 32(5):645-9; discussion 649-50. PubMed ID: 16706759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of botulinum A toxin to ameliorate facial kinetic frown lines.
    Foster JA; Barnhorst D; Papay F; Oh PM; Wulc AE
    Ophthalmology; 1996 Apr; 103(4):618-22. PubMed ID: 8618761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum Toxin Type-A (BoNT-A) Injections of the Corrugator Muscles for Aesthetics and Depression?
    Brennan C
    Plast Surg Nurs; 2016; 36(4):167-169. PubMed ID: 27922559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing.
    Lowe NJ; Yamauchi PS; Lask GP; Patnaik R; Moore D
    J Cosmet Laser Ther; 2002 Mar; 4(1):15-8. PubMed ID: 12079632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin type A injections: a randomized controlled study.
    Gassner HG; Sherris DA
    Mayo Clin Proc; 2000 Jul; 75(7):701-4. PubMed ID: 10907385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anatomical Proposal for Botulinum Neurotoxin Injection for Glabellar Frown Lines.
    Yi KH; Lee JH; Hu HW; Kim HJ
    Toxins (Basel); 2022 Apr; 14(4):. PubMed ID: 35448877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin for the management of depression: An updated review of the evidence and meta-analysis.
    Schulze J; Neumann I; Magid M; Finzi E; Sinke C; Wollmer MA; Krüger THC
    J Psychiatr Res; 2021 Mar; 135():332-340. PubMed ID: 33578275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin therapy of bipolar depression: A case series.
    Finzi E; Kels L; Axelowitz J; Shaver B; Eberlein C; Krueger TH; Wollmer MA
    J Psychiatr Res; 2018 Sep; 104():55-57. PubMed ID: 29982082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Masking" our emotions: Botulinum toxin, facial expression, and well-being in the age of COVID-19.
    Nestor MS; Fischer DL; Arnold D
    J Cosmet Dermatol; 2020 Sep; 19(9):2154-2160. PubMed ID: 32592268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of botulinum toxin dose with neurophysiological parameters of efficacy and safety in the glabellar muscles: a double-blind, placebo-controlled, randomized study.
    Alimohammadi M; Andersson M; Punga AR
    Acta Derm Venereol; 2014 Jan; 94(1):32-7. PubMed ID: 23975053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines.
    Carruthers JD; Lowe NJ; Menter MA; Gibson J; Eadie N;
    Plast Reconstr Surg; 2003 Sep; 112(4):1089-98. PubMed ID: 12973229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
    Prager W; Rappl T
    J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurophysiological Measures of Efficacy and Safety for Botulinum Toxin Injection in Facial and Bulbar Muscles: Special Considerations.
    Alimohammadi M; Punga AR
    Toxins (Basel); 2017 Oct; 9(11):. PubMed ID: 29084148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
    Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
    Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.